Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Breast 1

Conditions

Carcinoma, Renal Cell 74Kidney Neoplasms 27Prostatic Neoplasms 16Neoplasm Metastasis 11Urinary Bladder Neoplasms 5Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Neuroendocrine Tumors 3Carcinoma, Transitional Cell 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Margins of Excision 2Insulinoma 2Glucagonoma 2Gastrinoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Islet Cell 2Urothelial Cancer 1Ureteral Neoplasms 1Tuberous Sclerosis 1Thrombocytosis 1Testicular Neoplasms 1Renal Cell Cancer Metastatic 1Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1Primary Myelofibrosis 1

Interventions

pembrolizumab 6Radiosurgery 5Docetaxel 5enzalutamide 4darolutamide 3Radiotherapy 3Everolimus 3Androgen Antagonists 3relugolix 2luprolide acetate gel depot 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Image-Guided 2Radiofrequency Ablation 2Panobinostat 2Leuprolide 2Abiraterone Acetate 2trastuzumab deruxtecan 1talazoparib 1spartalizumab 1siremadlin 1sipuleucel-T 1sargramostim 1resiquimod 1polysaccharide-K 1poly ICLC 1palbociclib 1olaparib 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × Everolimus × Genitourinary × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

NCT00688753 2016-09-02

MACS0460

Novartis

Phase 2 Completed
92 enrolled 12 charts
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡